Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. - Wikidata - awgldk - TriplyDB

Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension.

Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q34275313

about

Cardiac energy metabolic alterations in pressure overload-induced left and right heart failure (2013 Grover Conference Series)Molecular mechanisms of pulmonary arterial remodeling A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?The genetics of pulmonary arterial hypertension Right ventricular adaptation and failure in pulmonary arterial hypertension.Role of oxidized lipids in pulmonary arterial hypertension Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature.Identifying "super responders" in pulmonary arterial hypertension.Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension.Mechanisms of right heart failure-A work in progress and a plea for failure prevention An official American Thoracic Society Statement: pulmonary hypertension phenotypes Mitochondrial dynamics in pulmonary arterial hypertension.The genetics of pulmonary arterial hypertension in the post-BMPR2 era.Epigenetic mechanisms of pulmonary hypertension.Diagnosing and treating the failing right heart.Epoprostenol sodium for treatment of pulmonary arterial hypertension.Right ventricular remodeling in idiopathic and scleroderma-associated pulmonary arterial hypertension: two distinct phenotypes.Heart Rate Variability is Related to Disease Severity in Children and Young Adults with Pulmonary Hypertension.QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension.Severe Pulmonary Arteriopathy Is Associated with Persistent Hypoxemia after Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension.FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate The pulmonary hypertension academic research consortium Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension.Combination therapy in pulmonary arterial hypertension: do we have the right strategy?Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study.Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle.Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice.Melatonin as a preventive and curative therapy against pulmonary hypertension.Spontaneous ventricular fibrillation in right ventricular failure secondary to chronic pulmonary hypertension.Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension.Mechanisms of right heart disease in pulmonary hypertension (2017 Grover Conference Series).Commentary on symptom experience of pulmonary arterial hypertension (PAH) patients.Dynamic and Diverse Changes in the Functional Properties of Vascular Smooth Muscle Cells in Pulmonary Hypertension.The Dark Side of the Moon: The Right Ventricle.Quantitative assessment of right ventricular glucose metabolism in idiopathic pulmonary arterial hypertension patients: a longitudinal study.

P2860

Q26825047-A08CB6C3-015D-472B-BF9A-725C31148D3D Q26991806-B6C66D30-6BD4-4483-A230-FB7EF269BB1E Q27026643-2360C98E-04D5-400B-BCD6-41C1DD7BA119 Q27027507-603F65C2-39E1-4044-BB79-F6EF445D3EC8 Q27318422-7188ECAF-6ADA-4977-A289-D89E4DE1795F Q28078566-23EB9C69-F704-4E6E-A3CE-5874C3477589 Q28083183-00B65B18-14F3-41B0-93ED-22A7818CD437 Q30248878-F88A0FFE-16B9-4A54-9F45-3AE509B6C09B Q30585014-D59FCC60-740B-412B-9632-DFAB37CF0D93 Q33165207-5625C166-4F35-4B19-A5AB-24AF48515439 Q33788452-911208B7-9DD8-41E1-8133-D9326546E200 Q34084566-C3D4C32C-AA02-42D9-AEC2-ED2317747646 Q34343977-B19BCF61-5DAA-4188-94BE-5F9DE070B376 Q34919733-70D2A13B-E96E-4229-917A-5D7E491D20E8 Q35116543-AA148FA2-8A48-40DD-A17D-2DC424E897AE Q35573919-9D1F5C52-CD21-41D0-9A76-D7C527C951AB Q35573935-A5EB7FA8-BB33-4EDF-8171-2FA49E9C9A28 Q35599768-0C993E28-2244-4005-87B1-FE934BF68C63 Q35624220-1B79BA26-004F-40AB-85D6-ACE1C4735C86 Q35665758-D4888C2C-E27C-4744-A196-819BDB9BD5D5 Q35824146-A2F597BF-5F11-47AF-972E-74DAAF1613EE Q36075721-CF8FE67E-0E3F-498F-87FF-17F297247425 Q36115857-8F515044-158D-49CC-88F4-F2EADD8C2286 Q36644468-8A76CBBE-3E63-4A78-9EF6-80A49326EA8A Q36810808-114AC5C3-1465-458A-99CE-68BF76C90E38 Q37699659-B401892D-C91C-4891-BDD3-AA367FE773BA Q37867668-82E60F10-AE59-4B0E-A160-D82FBABB7F9A Q37987390-6D8FD09F-ADB7-46CF-A3EC-8B0FCB7B7EF5 Q40096264-D597F653-8039-4316-B32A-9AB8E4B97FF1 Q40302879-2B18B5ED-6DF8-490A-AE96-CADFF5E1146D Q40404676-421142C0-63EF-4FBF-8EFD-1790D3F7B2A0 Q40708102-8BC439F8-48D4-40EF-B9A1-64D30631A0DE Q42556941-08D912BC-4D28-4AB9-BCDF-D612445091AC Q42592575-F1FC6808-70A0-401F-913A-1F35988E387E Q47094314-0EA3D19B-BF0D-4332-9A5C-EE9D491B31A7 Q47674512-938B63D7-AC5F-44D8-8BBD-507BF40A47B8 Q48864127-63DFFA94-E4F6-4EC5-891A-69B1C3354ACB Q49552882-F552A9B2-E5FC-4ACD-A245-9E037C628571 Q49634236-6856A9DE-8C77-459F-B1FC-FC59BB9C79B6 Q52988173-187FE0EE-33F0-4B8B-B590-0055EAEA0581

P2860

Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q34275313

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Long-term effects of epoproste ...... lmonary arterial hypertension.

@ast

Long-term effects of epoproste ...... lmonary arterial hypertension.

@en

Long-term effects of epoproste ...... lmonary arterial hypertension.

@nl

type

label

Long-term effects of epoproste ...... lmonary arterial hypertension.

@ast

Long-term effects of epoproste ...... lmonary arterial hypertension.

@en

Long-term effects of epoproste ...... lmonary arterial hypertension.

@nl

prefLabel

Long-term effects of epoproste ...... lmonary arterial hypertension.

@ast

Long-term effects of epoproste ...... lmonary arterial hypertension.

@en

Long-term effects of epoproste ...... lmonary arterial hypertension.

@nl

P1433

Q34275313-564AD5E9-71B2-4EAF-9F43-0A676EFAEE12

P1476

Q34275313-86B0FA2A-2CEB-4310-9998-BA352C0B64D1

P2093

Q34275313-4ADD377E-22AA-463C-8356-BFABAFF1DF66

Q34275313-75535F4D-2E4E-4A80-AACE-2A5ABFE955C2

Q34275313-C6DC7F52-6AE8-4C78-ADC8-8D17578BD637

Q34275313-D372075F-DD0F-4B65-906D-01501EA63379

Q34275313-DD187BB7-0520-46A7-9681-6296311E2A21

Q34275313-E16614AE-D7E9-4630-A688-9B0EE2561EB2

P2860

Q34275313-015D1D82-145E-4EA5-A5F0-38A5BF7171CA

Q34275313-07CC79FF-C2A1-42ED-BF7B-B417914D6C80

Q34275313-15FAEF07-8798-4CFB-A272-122AE2F24AA0

Q34275313-24EF0F3C-7CB5-4114-AD51-7B39C29D2668

Q34275313-603D994F-0D51-4687-9BBB-F63E9C464692

Q34275313-61520637-57DF-49AD-A876-4640AA16E100

Q34275313-6C73E0E6-2BC8-4C11-B717-828DD4572865

Q34275313-8E1F1CB8-2878-4B8F-8FCB-D7F73C912D2F

Q34275313-93A3ECD4-D650-411E-94B7-C3B5FDD53AFC

Q34275313-ACA321F6-9905-410F-8AD8-BD20AB924A7F

P304

Q34275313-6D6B3D41-CFC1-4AED-A577-E3B47202DEAA

P31

Q34275313-F746CFD2-0389-4C46-A8AA-CB49024706BA

Q34275313-b9f3e279-4a13-416a-a45c-0fc5ac86585b

P356

Q34275313-F0E067F6-E2F1-4129-A14C-096672A785DC

P407

Q34275313-DDFA25BC-5F5C-4522-99DF-FF7F3E1D3B3B

P433

Q34275313-85A87A80-58B9-4B00-A342-4D504163B53C

P478

Q34275313-900B3581-9835-420D-B323-EED3F31E9984

P577

Q34275313-A150CF65-CAF0-49ED-856E-F2F9F3A0B9E8

P5875

Q34275313-085D2E74-A597-4694-B689-6E6ADF5CFD95

P698

Q34275313-76C69CED-44CC-458E-85F5-AE3E09F059F9

P932

Q34275313-99B5FE7F-A140-49EF-8D0B-E1E4F60A196B

P356

P1433

P1476

Long-term effects of epoproste ...... lmonary arterial hypertension.

@en

P2093

Aliya N Husain

http://www.w3.org/2001/XMLSchema#string

Jennifer Pogoriler

http://www.w3.org/2001/XMLSchema#string

Mardi Gomberg-Maitland

http://www.w3.org/2001/XMLSchema#string

Peter T Toth

http://www.w3.org/2001/XMLSchema#string

Stephen L Archer

http://www.w3.org/2001/XMLSchema#string

Stuart Rich

http://www.w3.org/2001/XMLSchema#string

P2860

Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade

Calcium regulatory proteins and their alteration by transgenic approaches.

Mechanisms and models in heart failure: the biomechanical model and beyond.

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension

Treatment of pulmonary arterial hypertension.

The current treatment of pulmonary arterial hypertension: time to redefine success.

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

Proliferating cell nuclear antigen: a proteomics view.

Metabolic remodelling of the failing heart: beneficial or detrimental?

P304

1234-1239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1378/CHEST.09-2815

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

138

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47678978

http://www.w3.org/2001/XMLSchema#string

P698

21051399

http://www.w3.org/2001/XMLSchema#string

P932

2972625

http://www.w3.org/2001/XMLSchema#string